Monte Rosa Therapeutics (GLUE) Projected to Post Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) is expected to be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.27) per share for the quarter.

Monte Rosa Therapeutics Trading Up 3.6 %

Shares of Monte Rosa Therapeutics stock opened at $6.06 on Thursday. The firm has a market cap of $372.31 million, a P/E ratio of -3.31 and a beta of 1.46. Monte Rosa Therapeutics has a 12 month low of $3.21 and a 12 month high of $12.40. The stock’s fifty day moving average price is $6.25 and its 200-day moving average price is $6.75.

Analyst Ratings Changes

A number of brokerages recently weighed in on GLUE. Wells Fargo & Company downgraded Monte Rosa Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $14.00 to $11.00 in a research report on Thursday, December 19th. Wedbush restated an “outperform” rating and issued a $15.00 price objective on shares of Monte Rosa Therapeutics in a research note on Thursday, November 7th.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.